Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Research and Markets: Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H2 2012

Research and Markets
Posted on: 12 Oct 12

Research and Markets (http://www.researchandmarkets.com/research/sjwk4l/postpolycythemia) has announced the addition of Global Markets Direct's new report "Post-polycythemia vera myelofibrosis (PPV-MF) - Pipeline Review, H2 2012" to their offering.

Global Markets Direct's, 'Post-polycythemia vera myelofibrosis (PPV-MF) - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Post-polycythemia vera myelofibrosis (PPV-MF), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Post-polycythemia vera myelofibrosis (PPV-MF). Post-polycythemia vera myelofibrosis (PPV-MF) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Scope:

- A snapshot of the global therapeutic scenario for Post-polycythemia vera myelofibrosis (PPV-MF).

- A review of the Post-polycythemia vera myelofibrosis (PPV-MF) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Post-polycythemia vera myelofibrosis (PPV-MF) pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Reasons to Buy:

- Identify and understand important and diverse types of therapeutics under development for Post-polycythemia vera myelofibrosis (PPV-MF).

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.

- Devise corrective measures for pipeline projects by understanding Post-polycythemia vera myelofibrosis (PPV-MF) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

For more information visit http://www.researchandmarkets.com/research/sjwk4l/postpolycythemia

Source: Global Markets Direct

Business Wire
http://www.businesswire.com/

Last updated on: 12/10/2012

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.